57.29
Halozyme Therapeutics Inc stock is traded at $57.29, with a volume of 1.27M.
It is down -2.55% in the last 24 hours and down -12.08% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$58.79
Open:
$58.74
24h Volume:
1.27M
Relative Volume:
0.92
Market Cap:
$7.58B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
18.97
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
-6.68%
1M Performance:
-12.08%
6M Performance:
+10.66%
1Y Performance:
+48.27%
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
HALO
Halozyme Therapeutics Inc
|
57.29 | 7.58B | 947.36M | 392.47M | 392.71M | 3.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
Feb-29-24 | Initiated | TD Cowen | Outperform |
Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
Jul-24-23 | Initiated | H.C. Wainwright | Buy |
May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Mar-27-23 | Resumed | Berenberg | Buy |
Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
Dec-21-22 | Resumed | Morgan Stanley | Overweight |
Nov-28-22 | Initiated | Wells Fargo | Overweight |
Sep-09-22 | Initiated | Morgan Stanley | Overweight |
May-23-22 | Initiated | SVB Leerink | Outperform |
Jun-14-21 | Initiated | Evercore ISI | Outperform |
May-17-21 | Initiated | SVB Leerink | Outperform |
May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Jan-21-21 | Reiterated | The Benchmark Company | Buy |
Dec-17-20 | Initiated | Berenberg | Buy |
Sep-14-20 | Resumed | JP Morgan | Overweight |
Jul-01-20 | Initiated | The Benchmark Company | Buy |
Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jan-08-20 | Initiated | Goldman | Buy |
Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
Oct-19-18 | Resumed | Piper Jaffray | Neutral |
May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
Jan-24-18 | Initiated | Goldman | Neutral |
Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
Nov-03-16 | Initiated | Deutsche Bank | Buy |
Dec-04-15 | Initiated | Wells Fargo | Outperform |
Nov-18-15 | Initiated | Citigroup | Buy |
Sep-22-15 | Initiated | Barclays | Overweight |
Jun-22-15 | Reiterated | JP Morgan | Overweight |
Mar-03-15 | Reiterated | UBS | Buy |
Feb-18-15 | Reiterated | MLV & Co | Buy |
Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet - simplywall.st
If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity - Yahoo Finance
Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market - MSN
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Pre - GuruFocus
Peering Into Halozyme Therapeutics's Recent Short Interest - Benzinga
Argenx stock rises on FDA nod for Vyvgart Hytrulo (ARGX) - Seeking Alpha
Halozyme Therapeutics Reports FDA Approval for Self-Injectable Syringe Developed in Partnership With Argenx - marketscreener.com
Halozyme :FDA Oks Argenx' VYVGART Hytrulo Prefilled Syringe For Generalized Myasthenia Gravis & CIDP - Nasdaq
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - Citizen Tribune
J&J, Halozyme win EU nod for injectable Rybrevant in lung cancer - MSN
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewswire Inc.
Game-Changing FDA Approval: New Self-Injectable Treatment Transforms Rare Disease Care - Stock Titan
Halozyme Therapeutics (HALO) Gains EU Approval for Injectable Co - GuruFocus
J&J, Halozyme get EU nod for Darzalex SC to treat multiple myeloma - Seeking Alpha
European Commission Approved Subcutaneous Darzalex (Daratumumab) Based Quadruplet Regimen - marketscreener.com
Halozyme Reports EC Approval For Indication Extension Of DARZALEX Co-formulated With ENHANZE - Nasdaq
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - Quantisnow
Halozyme Therapeutics : Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing 's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Bre - MarketScreener
Halozyme Therapeutics : To Receive $10 Million Milestone Payment From Janssen - MarketScreener
Halozyme (HALO) Secures European Approval for J&J Antitumor Inje - GuruFocus
EC approves new lung cancer treatment using Halozyme technology By Investing.com - Investing.com South Africa
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - The Malaysian Reserve
Halozyme Says EC Approved Subcutaneous Rybrevant For Advanced EGFR-Mutated NSCLC - Nasdaq
EC approves new lung cancer treatment using Halozyme technology - Investing.com
European Commission Approves Subcutaneous Rybrevant® (Amivantamab) - MarketScreener
KLP Kapitalforvaltning AS Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock - Investing.com Australia
Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock By Investing.com - Investing.com South Africa
4,812 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by EntryPoint Capital LLC - MarketBeat
Corebridge Financial Inc. Has $9.81 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Long Term Trading Analysis for (HALO) - news.stocktradersdaily.com
Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion For New Cancer Drug Delivery Method - Nasdaq
Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications - Quantisnow
Major Breakthrough: New Cancer Drug Delivery Method Gets EU Panel Support - Stock Titan
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance
Merck plans to launch US subcutaneous version of Keytruda on October 1 - Reuters
Halozyme Therapeutics (HALO) Stock Price, News & Analysis - MarketBeat
Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Halozyme stock soars to all-time high of $65.54 By Investing.com - Investing.com South Africa
Halozyme stock soars to all-time high of $65.54 - Investing.com India
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Halozyme Announces Retirement of Chief Technical Officer - TipRanks
Halozyme announces CTO retirement, effective immediately - Investing.com India
Halozyme announces CTO retirement, effective immediately By Investing.com - Investing.com Australia
Drug developers show mixed performance in early 2025 - BioWorld MedTech
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Halozyme Joins the $1 Billion Club - Yahoo Finance
AstraZeneca signs $1.35B Alteogen deal for subcutaneous cancer drugs - Fierce Pharma
Halozyme Therapeutics: Steady Growth In A Challenged Market (NASDAQ:HALO) - Seeking Alpha
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):